Transcriptome profiling and experimental validation identify FOS, RAC2, and TYROBP as potential biomarkers for Fu’s subcutaneous needling in neuropathic pain treatment
Molecular Pain · 2026-06 · 22
DOI: 10.1177/17448069261459255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, online erschienen am 03.06.2026. Verfasst von Huiqin Fang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, Chi…. Hauptthemen laut MEDLINE: Neuralgia, Biomarkers, Gene Expression Profiling, Acupuncture Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Shenzhen Municipal Science and Technology Program Project, the Traditional Chinese Medicine Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine, the Medical and Health Research Project of Bao'an District Medical Association in Shenzhen.
Abstract (Originalsprache)
Background
This study aimed to explore potential biomarkers and mechanisms underlying in the treatment of neuropathic pain (NP) with Fu’s subcutaneous needling (FSN), employing a transcriptomics approach.
Methods
In this study, RNA sequencing was performed in a rat model of chronic constriction injury treated with FSN and acupuncture methods. The FSN-related genes in the treatment of NP with FSN were obtained by overlapping the results of differential expression analysis. Potential biomarkers were identified by protein-protein interaction (PPI) analysis and machine learning. In addition, potential biomarkers were analyzed for functional enrichment, molecular regulatory networks, and drug prediction. Reverse transcription quantitative PCR (RT-qPCR) was employed to validate the expression levels of the biomarkers.
Results
FOS, RAC2, and TYROBP were identified as potential biomarkers. Furthermore, mo-miR-92a-2-5p was predicted to co-target RAC2 and TYROBP. Twenty-five drugs were predicted to target FOS and four drugs were predicted to target RAC2 were also identified. FSN treatment enhanced and attenuated the expression of RAC2, TYROBP, and FOS, respectively.
Conclusion
In this study, FOS, RAC2, and TYROBP were identified as potential biomarkers in the treatment of NP with FSN, providing a potential theoretical basis for NP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
- Encephalopathy Rehabilitation Department, Weifang Traditional Chinese Medicine Hospital, Weifang, Shandong, China.
- General Medicine, Bao'an Authentic TCM Therapy Hospital, Shenzhen, Guangdong, China.
- Institute of Integrated Medicine, Qingdao University, Qingdao, Shandong, China.
- Clinical Division of the School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
ORCID-Profile: Huiqin Fang, Yaping Li, Yarong Sun, Yunhua Zang
Förderung
- the Shenzhen Municipal Science and Technology Program Project
- the Traditional Chinese Medicine Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine
- the Medical and Health Research Project of Bao'an District Medical Association in Shenzhen
Zitieren
APA
Fang, H., Li, Y., Li, J., Sun, Y., & Zang, Y. (2026). Transcriptome profiling and experimental validation identify FOS, RAC2, and TYROBP as potential biomarkers for Fu’s subcutaneous needling in neuropathic pain treatment. Molecular Pain, 22. https://doi.org/10.1177/17448069261459255
Vancouver
Fang H, Li Y, Li J, Sun Y, Zang Y. Transcriptome profiling and experimental validation identify FOS, RAC2, and TYROBP as potential biomarkers for Fu’s subcutaneous needling in neuropathic pain treatment. Molecular Pain. 2026;22. doi:10.1177/17448069261459255
BibTeX
@article{Fang2026,
author = {Fang, Huiqin and Li, Yaping and Li, Jiaqi and Sun, Yarong and Zang, Yunhua},
title = {Transcriptome profiling and experimental validation identify FOS, RAC2, and TYROBP as potential biomarkers for Fu’s subcutaneous needling in neuropathic pain treatment},
journal = {Molecular Pain},
year = {2026},
volume = {22},
doi = {10.1177/17448069261459255}
}
EUVIMED